Compare NCRA & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NCRA | CMMB |
|---|---|---|
| Founded | 2002 | 2004 |
| Country | Taiwan | Israel |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6M | 11.1M |
| IPO Year | 2022 | 2023 |
| Metric | NCRA | CMMB |
|---|---|---|
| Price | $1.42 | $1.52 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | ★ 2.2M | 217.7K |
| Earning Date | 04-15-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | ★ $13,627,944.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $39.00 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.06 | $0.87 |
| 52 Week High | $2.68 | $3.86 |
| Indicator | NCRA | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 67.28 | 42.24 |
| Support Level | $0.86 | N/A |
| Resistance Level | $1.74 | $1.83 |
| Average True Range (ATR) | 0.19 | 0.27 |
| MACD | 0.05 | -0.05 |
| Stochastic Oscillator | 50.43 | 1.82 |
Nocera Inc is engaged in the manufacturing of aquaculture equipment, construction of aquaculture facilities, managing and operating aquaculture facilities, and consulting for third-party operators of aquaculture facilities. Its primary business operations consist of the design, development, and production of RASs large-scale fish tank systems, for fish farms along with consulting, technology transfer, and aquaculture project management services to new and existing aquaculture management business services.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.